ARS Pharmaceuticals, Inc
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions. The company is involved in the development of neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. T… Read more
ARS Pharmaceuticals, Inc (SPRY) - Total Liabilities
Latest total liabilities as of September 2025: $225.15 Million USD
Based on the latest financial reports, ARS Pharmaceuticals, Inc (SPRY) has total liabilities worth $225.15 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
ARS Pharmaceuticals, Inc - Total Liabilities Trend (2018–2024)
This chart illustrates how ARS Pharmaceuticals, Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
ARS Pharmaceuticals, Inc Competitors by Total Liabilities
The table below lists competitors of ARS Pharmaceuticals, Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sumitomo Pharma Co. Ltd
PINK:SMDPY
|
USA | $526.94 Billion |
|
Altarea
LSE:0IRK
|
UK | €4.88 Billion |
|
ZHEJIANG ASIA-PACIFIC MECHANICAL & ELECTRONIC CO LTD
SHE:002284
|
China | CN¥4.79 Billion |
|
United Parks & Resorts Inc
NYSE:PRKS
|
USA | $3.05 Billion |
|
Streamax Technology Co Ltd
SHE:002970
|
China | CN¥1.25 Billion |
|
CVR Energy Inc
NYSE:CVI
|
USA | $2.90 Billion |
|
PLUXEE NV
PA:PLX
|
France | €5.93 Billion |
|
Kiwi Property Group Limited
PINK:KWIPF
|
USA | $865.29 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down ARS Pharmaceuticals, Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.52 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.60 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ARS Pharmaceuticals, Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ARS Pharmaceuticals, Inc (2018–2024)
The table below shows the annual total liabilities of ARS Pharmaceuticals, Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $94.36 Million | +3786.12% |
| 2023-12-31 | $2.43 Million | -71.60% |
| 2022-12-31 | $8.55 Million | -90.78% |
| 2021-12-31 | $92.72 Million | +129.16% |
| 2020-12-31 | $40.46 Million | +90.40% |
| 2019-12-31 | $21.25 Million | +127.27% |
| 2018-12-31 | $9.35 Million | -- |